SM
BDRX

Sabby Management’s Biodexa Pharmaceuticals BDRX Stock Holding History

Sabby Management’s Portfolio BDRX Stock Details BDRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-51,494
Closed -$159K – 25
2026
Q1 		$159K Buy
51,494
+13,362
+35% +$94K 0.35% 16
2025
Q4 		$433K Buy
+38,132
New +$1.09M 0.62% 15

Other funds holding BDRX

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
APW
Allied Private Wealth Boca Raton, Florida $156M AUM
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
HHCP
Hilton Head Capital Partners Hilton Head Island, South Carolina $198M AUM
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

Sabby Management's BDRX Position: Q2 2026 in Review

Sabby Management sold out of Biodexa Pharmaceuticals (BDRX) in Q2 2026, closing a stake of 51,494 shares — an estimated $159K sold.

Sabby Management first reported a position in BDRX in Q4 2025 and held it in 2 quarters. The position peaked at $433K in Q4 2025. 8 funds tracked by Wall St. Rank hold BDRX as of Q2 2026.

  • Sabby Management reported no remaining Biodexa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Sabby Management sold 51,494 Biodexa Pharmaceuticals shares in Q2 2026, an estimated $159K.
  • Sabby Management first reported a position in Biodexa Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Sabby Management's Biodexa Pharmaceuticals position peaked at $433K in Q4 2025.
  • 8 funds tracked by Wall St. Rank held Biodexa Pharmaceuticals as of Q2 2026.

Based on Sabby Management's 13F filing for Q2 2026, filed 14 Aug 2026.